Clinical trials
Lung Cancer Non-Small Cell Cancer (NSCLC) clinical trials
Below are recruiting lung cancer non-small cell cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 874 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06634056RecruitingPhase 2
Preventing lung inflammation during chemoradiation for stage III lung cancer
This trial tests whether two medicines, pentoxifylline and vitamin E, can help prevent a type of lung inflammation called pneumonitis in people with stage III non-small cell lung cancer who are getting chemoradiation and a checkpoint inhibitor. These medicines are already used for other conditions and may lower the risk of this side effect.
Toronto, OntarioAges 18 years+ - NCT05401110RecruitingPhase 1
Osimertinib plus antibody treatment for EGFR-mutated lung cancer
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Beverly Hills, CaliforniaAges 18 years+ - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT07751536Recruiting
Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
Hefei, AnhuiAges 18–75 - NCT04762199RecruitingPhase 1
MRX-2843 with osimertinib for EGFR-mutant lung cancer
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
Atlanta, GeorgiaAges 18 years+ - NCT07754812RecruitingPhase 4
Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 70 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT07668752RecruitingPhase 3
New pill (GFH375) vs chemo for KRAS G12D lung cancer
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT06567704Recruiting
Fatigue from immunotherapy in lung cancer: a patient interview study
This study aims to understand how maintenance immunotherapy affects fatigue in people with non-small cell lung cancer. Researchers will talk with patients to learn about their experiences.
Charlotte, North CarolinaAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT07382726RecruitingPhase 1
Study of izalontamab brengitecan plus adagrasib for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to a previous KRAS G12C inhibitor. The goal is to see if the combination is safe and works better than the single drug alone.
Houston, TexasAges 18 years+ - NCT07505173RecruitingPhase 2
Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
TianjinAges 18–75 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT07697586RecruitingPhase 2
Two new drugs for advanced lung cancer without EGFR or ALK
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
Jilin CityAges 18–75 - NCT07354061RecruitingPhase 1/Phase 2
Ensartinib plus chemo before surgery for ALK+ lung cancer
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Xi’an, ShanxiAges 18–75 - NCT05145244Recruiting
Copenhagen observational study for lung or breast cancer data
This is an observational study that collects real-world information from adults with lung cancer or breast cancer. It may help doctors better understand how people do over time and how treatments and outcomes relate to details from your medical record and tests.
CopenhagenAges 18 years+ - NCT07460999Recruiting
Singing training after lung cancer surgery
This trial tests if singing training twice a week can help with ongoing symptoms like shortness of breath or fatigue 6 to 18 months after surgery for early-stage lung cancer.
CopenhagenAges 18 years+ - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75
Hear when a new Lung Cancer Non-Small Cell Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer non-small cell cancer (nsclc)?
- Yes. Clin2 currently lists 874 recruiting lung cancer non-small cell cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer non-small cell cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer non-small cell cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.